About Epiminder
Epiminder is a publicly listed company based in Melbourne (Australia) founded in 2018. It operates as an an implantable EEG device is developed for monitoring epileptic seizures. It operates in the Healthcare and Technology sectors. Epiminder has raised $24.54 million across 2 funding rounds from investors including Cochlear, Seer Medical and University of Melbourne. Its chief executive is Rohan Hoare. Epiminder offers products and services including Minder. Its focus areas include Life Sciences, Neurology, Medical Devices and Screening Devices. Its competitors include Ceribell, Empatica, Seer, Epitel and Neurava and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Epiminder was founded in 2018 and is based in Melbourne, Australia. Operations are centered in the medical device sector, where an implantable sub-scalp system known as Minder is developed for EEG monitoring. Brain electrical activity linked to epileptic seizures is recorded using this technology. Focus remains on neurodiagnostic tools to support epilepsy management in clinical settings.
- Headquarters Melbourne, Australia
- Stage Public
- SectorsHealthcareTechnology
- Website epiminder.com
- Social LinkedIn X
- Legal Name Epiminder Ltd
- Net Profit-$29.43 M (USD)-34.47as on Jun 30, 2026
- EBITDA-$30.03 M (USD)-62.33as on Jun 30, 2026
- Total Equity Funding$24.54M (USD)
in 2 rounds
- Latest Funding Round$11.66M (USD), Series A
Mar 2022
- InvestorsCochlear
& 4 more
Products & Services of Epiminder
Epiminder offers a comprehensive portfolio of products and services, including Minder.
Implantable system for continuous brain activity monitoring in epilepsy.
Funding Insights of Epiminder
Epiminder has successfully raised a total of $24.54M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.66 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.54M
- Total Rounds 2
- Last Round Series A — $11.66M
- First Round $12.88M
(Oct 2020)
- Investors Count 5
All 2 funding rounds of Epiminder with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $11.66M | Series A | – | Cochlear, University of Melbourne | – |
| Oct 2020 | $12.88M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Epiminder
Epiminder has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Cochlear, Seer Medical and University of Melbourne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Electronic hearing devices and implants are developed for hearing loss. | 1981 | cochlear.com | Mumbai, India | |
Diverse courses and degrees are offered across multiple academic streams. | 1853 | unimelb.edu.au | United States | |
Cloud-based wearable devices are utilized for epilepsy diagnosis and management. | 2017 | seermedical.com | Melbourne, Australia | |
Conducts medical research and develops devices for autoimmune, brain, and sensory disorders. | 1986 | bionicsinstitute.org | Melbourne, Australia | |
Multispecialty hospital services are delivered in Fitzroy, Australia. | 1893 | svhm.org.au | Fitzroy, Australia |
Investor details for Epiminder
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Epiminder
11 people are tracked at Epiminder (5 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Rohan Hoare | CEO | Leadership |
John Heasman | Chief Operating Officer | Leadership |
Steven Ringo | VP Software & AI | Leadership |
Chip Moebus | Vice President Of Market Access | Leadership |
Holly Fontenot | Director, Clinical Trials | Leadership |
Neetu Pal | Test Practice Lead | Team |
Alex Maras | Principal Software Engineer | Team |
Lex Willcocks | Principal Data Analyst | Team |
Angus Leche | Principal System Engineer | Team |
Yashita Girhotra | Quality Manager | Team |
Andrew Niemiec | Senior Product Engineer | Team |
Complete people profiles for Epiminder
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Epiminder
Epiminder is a publicly listed company on the ASX with ticker symbol EPI in Australia. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Dec 2025
- Listed onASX: EPI
- Listed entityEPIMINDER LTD
- ISINAU0000432239
- Share price0.28 AUD (-1.75% on the day) · 2026-10-14
- Market capitalisation61,751,423.00 AUD
- EPS (diluted, trailing year)-0.20 AUD
- Volume (last session)5,587
Financials of Epiminder
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | – | -42.7M AUD | -43.6M AUD |
| 2025 | – | -31.8M AUD | -26.9M AUD |
| 2024 | – | -15.9M AUD | -20.5M AUD |
| 2023 | – | -16.1M AUD | -19.9M AUD |
Detailed financial statements for Epiminder
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Epiminder
4 dated milestones of Epiminder across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Epiminder is founded.
- Funding First funding round of $12.9M.
- Funding Latest funding round, Series A, of $11.7M.
- IPO Lists on the stock exchange (IPO).
Competitors of Epiminder
Epiminder has 10 listed competitors in our database, 9 of them funded. They include Ceribell, Empatica, Seer, Epitel and Neurava, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ceribell.com | 2014 | Mountain View, United States | $187.52M | 218 | Portable EEG devices for point-of-care seizure diagnosis are provided. | |
| empatica.com | 2011 | Milano, Italy | $30.95M | – | Developer of a wrist band to monitor physiological signals | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. | |
| epitel.com | 2007 | Salt Lake, United States | $12.5M | – | Wearable EEG system for epilepsy monitoring and control is provided. | |
| neurava.com | 2019 | West Lafayette, United States | $5.78M | – | Remote monitoring platform for epilepsy patients | |
| profusa.com | 2009 | San Francisco, United States | $62.16M | 15 | Biochemical sensors are developed for real-time chronic disease monitoring. | |
| n1mtc.com | 2017 | Eden Prairie, United States | – | – | AI-enabled diagnostic and treatment devices for neurological diseases are developed. | |
| injectsense.com | 2014 | Emeryville, United States | $16.43M | 15 | Sensor-coupled platform is utilized for disease tracking and therapy management. | |
| neuroeventlabs.com | 2015 | Tampere, Finland | $6.59M | – | AI-based seizure monitoring | |
| synerfuse.com | 2015 | Minneapolis, United States | $6.61M | 5 | Pain management implants and platforms are provided for healthcare professionals. |
Detailed competitors of Epiminder
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Epiminder
The website of Epiminder (epiminder.com) receives about 3.4K visits a month.
- Monthly visits3.4K
▼ 30% vs previous month
Top companies in Clinical IT & Data Platforms
10 companies that operate in the same segment as Epiminder (Clinical IT & Data Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of fitness memberships encompassing group classes, gyms, and at-home workouts | 2016 | Bengaluru, Karnataka, India | USD 716.99 M | – | 1,832 | |
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | – | – | |
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | – | 1,746 | |
Tech-enabled mental health solutions for employers are provided. | 2016 | New York, New York, United States | USD 473.73 M | – | 3,902 | |
App-based health insurance is offered to individuals and businesses. | 2016 | Paris, Ile de France, France | USD 863.12 M | – | 1,606 | |
Virtual care programs for managing chronic diseases are provided. | 2011 | San Francisco, California, United States | USD 450.12 M | USD 260.21 M | 992 | |
AI-driven EMR and practice management software is delivered for clinics. | 2010 | Boca Raton, Florida, United States | USD 329.17 M | – | 2,470 | |
Cloud-based administrative tools for healthcare providers are offered. | 1997 | Watertown, United States | USD 40 M | – | – | |
Membership-based primary care platform is offered for employees and consumers. | 2007 | San Francisco, California, United States | USD 402.56 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epiminder
Complete news archive for Epiminder
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epiminder
Epiminder was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Epiminder is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Rohan Hoare is the current CEO of Epiminder.
Epiminder is a funded company, having raised a total of $24.54M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12.88M, raised on Oct 2020.
Epiminder was founded in 2018 and is based in Melbourne, Australia. Operations are centered in the medical device sector, where an implantable sub-scalp system known as Minder is developed for EEG monitoring. Brain electrical activity linked to epileptic seizures is recorded using this technology. Focus remains on neurodiagnostic tools to support epilepsy management in clinical settings.
Epiminder offers Minder.
Yes, Epiminder is publicly traded on ASX under the ticker symbol EPI.
Epiminder has 5 investors. Key investors include Cochlear, Seer Medical, University of Melbourne, St Vincent's Hospital Melbourne, and Bionics Institute.